Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2025 Jan 8;1(1):CD012532.
doi: 10.1002/14651858.CD012532.pub2.

Anti-PD-1 and anti-PD-L1 antibodies for glioma

Suely M de Melo  1   2   3 , Mauricio En Elias Nunes da Silva  3 , Maria Regina Torloni  4 , Rachel Riera  5   6   7 , Kelly De Cicco  8 , Carolina Oc Latorraca  4 , Ana Carolina Pereira Nunes Pinto  3   4   9   10
Affiliations
Meta-Analysis

Anti-PD-1 and anti-PD-L1 antibodies for glioma

Suely M de Melo et al. Cochrane Database Syst Rev. .

Abstract

Background: Glioblastoma multiforme (GBM) is the most common and aggressive adult glioma (16-month median survival). Its immunosuppressive microenvironment limits the efficacy of immune checkpoint inhibitors (ICIs).

Objectives: To assess the effects of the ICIs antibodies anti-programmed cell death 1 (anti-PD-1) and anti-programmed cell death ligand 1 (anti-PD-L1) in treating adults with diffuse glioma.

Search methods: We searched CENTRAL, MEDLINE, Embase, and clinical trials registers on 8 March 2024.

Selection criteria: We included randomised controlled trials (RCTs) evaluating adults with diffuse glioma treated with anti-PD-1/PD-L1 compared to placebo or other therapies used alone or with other ICIs. Primary outcomes were overall survival (OS), progression-free survival (PFS), and serious adverse events (SAE). Secondary outcomes were overall response rate (ORR), quality of life (QoL), and less serious AEs.

Data collection and analysis: We followed standard Cochrane methods.

Main results: We included seven RCTs evaluating anti-PD-1 treatment in recurrent (N = 4) and newly diagnosed (N = 3) grade 4 glioma participants. The analysis encompassed 1953 participants; sample sizes ranged from 35 to 716. Meta-analyses were not possible due to heterogeneity and the small number of studies. Most trials had high risk of bias. Nivolumab versus bevacizumab in people with recurrent GBM (1 trial, 369 participants) Nivolumab probably does not increase OS (hazard ratio (HR) 1.04, 95% confidence interval (CI) 0.83 to 1.30; 1.3% more, 95% CI 6.30 fewer to 7.80 more; 369 participants; moderate-certainty evidence) or PFS (HR 1.97, 95% CI 1.57 to 2.48; 16.40% more, 95% CI 12.40 more to 19.00 more; 369 participants; moderate-certainty evidence). The evidence for SAE is very uncertain (risk ratio (RR) 1.20, 95% CI 0.74 to 1.92; 347 participants). Nivolumab probably does not increase ORR (RR 0.34, 95% CI 0.18 to 0.63; 309 participants; moderate-certainty evidence), but may not increase less serious AEs (RR 1.03, 95% CI 0.96 to 1.10; 347 participants; low-certainty evidence). Nivolumab plus bevacizumab 10 mg/kg versus nivolumab plus bevacizumab 3 mg/kg in people with recurrent GBM (1 trial, 90 participants) Nivolumab plus bevacizumab 10 mg/kg may not increase OS (HR 1.39, 95% CI 0.86 to 2.25; 9.90% more, 95% CI 5.20 fewer to 18.80 more; 90 participants; low-certainty evidence). The evidence for PFS (HR 1.23, 95% CI 0.78 to 1.93; 5.80% more, 95% CI 8.20 fewer to 14.20 more; 90 participants) and SAE (RR 1.19, 95% CI 0.79 to 1.79; 90 participants) is very uncertain. Nivolumab may not increase less serious AEs (RR 1.02, 95% CI 0.96 to 1.09; low-certainty evidence; 90 participants). Pembrolizumab plus bevacizumab versus pembrolizumab in people with recurrent GBM (1 trial, 80 participants) The evidence for OS (HR 1.03, 95% CI 0.65 to 1.63; 0.30% more, 95% CI 7.60 fewer to 2.90 more; 80 participants), PFS (HR 0.97, 95% CI 0.61 to 1.54: 0.40% fewer, 95% CI 9.20 fewer to 2.80 more; 80 participants), SAE (RR 1.32, 95% CI 0.75 to 2.42; 80 participants), and ORR (RR 12.76, 95% CI 0.77 to 210.27; 80 participants) is very uncertain. Pembrolizumab plus bevacizumab may not increase less serious AEs (RR 1.04, 95% CI 0.96 to 1.13; 80 participants; low-certainty evidence). Neoadjuvant (before surgical resection) and adjuvant (after surgical resection) pembrolizumab versus adjuvant-only pembrolizumab in people with recurrent GBM (1 trial, 35 participants) The evidence for OS (HR 0.39, 95% CI 0.17 to 0.92; 25.20% fewer, 95% CI 37.10 fewer to 2.10 fewer; 35 participants), PFS (HR 0.43, 95% CI 0.20 to 0.91; 30.10% fewer, 95% CI 52.20 fewer to 3.60 fewer; 35 participants), and SAE (RR 1.00, 95% CI 0.31 to 3.28; 32 participants) is very uncertain. Nivolumab plus radiotherapy versus temozolomide plus radiotherapy in people with newly diagnosed unmethylated GBM (1 trial, 560 participants) Nivolumab plus radiotherapy probably does not increase OS (HR 1.31, 95% CI 1.09 to 1.58 months; 8.30% more, 95% CI 2.80 more to 12.90 more; 560 participants) and PFS (HR 1.38, 95% CI 1.15 to 1.65 months; 7.50% more, 95% CI 3.60 more to 10.30 more; 560 participants; moderate-certainty evidence). The evidence for SAE is very uncertain (RR 0.87, 95% CI 0.65 to 1.18; 553 participants). It may not increase ORR (RR 1.08, 95% CI 0.43 to 2.69; 560 participants; low-certainty evidence) and probably does not increase less serious AEs (RR 1.00, 95% CI 0.96 to 1.04; 560 participants; moderate-certainty evidence). The evidence for time to deterioration of QoL is very uncertain (HR 0.76, 95% CI 0.59 to 0.99; 560 participants). Nivolumab plus temozolomide plus radiotherapy versus placebo plus temozolomide plus radiotherapy in people with newly diagnosed methylated GBM (1 trial, 716 participants) Nivolumab plus temozolomide plus radiotherapy probably does not increase OS (HR 1.10, 95% CI 0.92 to 1.32; 3.50 more, 95% CI 3.80 fewer to 9.60 more; 716 participants) and PFS (HR 1.10, 95% CI 0.92 to 1.32; 3.00 more, 95% CI 3.50 fewer to 7.90 more; 716 participants), and probably increases SAE (RR 2.91, 95% CI 2.05 to 4.12; 709 participants; moderate-certainty evidence). It does not increase less serious AEs (RR 1.02, 95% CI 1.00 to 1.04; 709 participants; high-certainty evidence). Adjuvant nivolumab plus temozolomide versus temozolomide in older people with GBM (1 trial, 103 participants) Nivolumab plus temozolomide probably does not increase OS (HR 0.85, 95% CI 0.54 to 1.33; 3.10 fewer, 95% CI 15.80 fewer to 3.60 more; 103 participants; moderate-certainty evidence) and PFS (HR 0.77, 95% CI 0.49 to 1.19; 5.40 fewer, 95% CI 19.10 fewer to 2.40 more; 103 participants; moderate-certainty evidence). The evidence for SAE is very uncertain (RR 1.58, 95% CI 0.88 to 2.81; 103 participants). The evidence for QoL is very uncertain (results only reported graphically; 103 participants).

Authors' conclusions: In recurrent GBM, nivolumab alone probably has no benefit. Anti-PD1 plus bevacizumab may also be ineffective based on low- to very low-certainty evidence. Neoadjuvant plus adjuvant pembrolizumab may improve OS and PFS, but this was based on only one small trial and very low-certainty evidence. In newly diagnosed GBM, nivolumab plus radiotherapy in unmethylated and plus radiotherapy plus temozolomide in methylated GBM probably has no benefit. In older participants, adjuvant nivolumab probably offers no benefit.

Trial registration: ClinicalTrials.gov NCT03452579 NCT02337491 NCT02017717 NCT04195139 https://clinicaltrials.gov/ct2/show/NCT02287428 https://clinicaltrials.gov/ct2/show/NCT04195139 https://www.clinicaltrials.gov/study/NCT04396860 https://classic.clinicaltrials.gov/ct2/show/NCT04729959 https://clinicaltrials.gov/study/NCT04888611 https://classic.clinicaltrials.gov/ct2/show/NCT05484622.

PubMed Disclaimer

Conflict of interest statement

SMM: received travel/accommodations/meeting expenses from Merck Sharp & Dohme that were unrelated to this review and previous to the first immune block results.

MENS: none known

MRT: none known

RR: none known

KDC: none known

COCL: none known

ACPNP: none known

Update of

  • doi: 10.1002/14651858.CD012532

References

References to studies included in this review

Ahluwalia 2021 {published data only}
    1. Ahluwalia M, Peereboom D, Schilero C, Forst D, Wong E, Wen P, et al. RBTT-01. Randomized phase 2 open label study of nivolumab plus standard dose bevacizumab versus nivolumab plus low dose bevacizumab in recurrent glioblastoma. Neuro-Oncology 2018;20(Suppl 6):vi234.
    1. Ahluwalia MS, Peereboom DM, Rauf Y, Li H, Wen PY, Reardon DA. Randomized phase II open label study of nivolumab plus standard dose bevacizumab vs nivolumab plus low dose bevacizumab in recurrent glioblastoma (RGBM). Nivolumab Benefits Older Population. Neuro-Oncology 2021;23(Suppl 6):vi52. [DOI: 10.1200/JCO.2021.39.15_suppl.2015] - DOI
    1. Ahluwalia MS, Rauf Y, Li H, Wen PY, Peereboom DM, Reardon DA. Randomized phase 2 study of nivolumab (nivo) plus either standard or reduced dose bevacizumab (bev) in recurrent glioblastoma (rGBM). Journal of Clinical Oncology 2021;39(15_suppl):2015.
    1. NCT03452579. Nivolumab plus standard dose bevacizumab versus nivolumab plus low dose bevacizumab in GBM. clinicaltrials.gov/study/NCT03452579.
Cloughesy 2019 {published data only}
    1. Cloughesy TF, Mochizuki AY, Orpilla JR, Hugo W, Lee AH, Davidson TB, et al. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nature Medicine 2019;25(3):477-86. [PMID: ] - PMC - PubMed
    1. Orpilla J, Mochizuki A, Reynoso J, Akkad N, Lee A, Davidson T, et al. ATIM-25. Neoadjuvant PD-1 antibody blockade is associated with focal upregulation of PD-L1 and CD8 T cell infiltrate in recurrent glioblastoma. Neuro-Oncology 2018;20(Suppl 6):vi6.
Lim 2022 {published data only}
    1. Lim M, Weller M, Idbaih A, Steinbach J, Finocchiaro G, Raval RR, Ansstas G, et al. Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter. Neuro-Oncology 2022;24(11):1-15. [DOI: 10.1093/neuonc/noac116] - DOI - PMC - PubMed
    1. NCT02667587. An Investigational Immuno-therapy study of temozolomide plus radiation therapy with nivolumab or placebo, for newly diagnosed patients with glioblastoma (GBM, a malignant brain cancer) (CheckMate548). clinicaltrials.gov/study/NCT02667587.
    1. Weller M, Lim M, Idbaih A, Steinbach J, Finocchiaro G, Raval R, et al. A randomized phase 3 study of nivolumab or placebo combined with radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma with methylated MGMT promoter: Checkmate 548. Neuro-Oncology 2021;23(Suppl 6):vi55-vi56.
Nayak 2021 {published data only}
    1. NCT02337491. Pembrolizumab +/- bevacizumab for recurrent GBM. clinicaltrials.gov/study/NCT02337491.
    1. Nayak L, Molinaro AM, Peters K, Clarke JL, Jordan JT, Groot J, et al. Randomized phase II and biomarker study of pembrolizumab plus bevacizumab versus pembrolizumab alone for patients with recurrent glioblastoma. Clinical Cancer Research 2021;27(4):1048-57. [DOI: 10.1158/1078-0432.CCR-20-2500] - DOI - PMC - PubMed
Omuro 2022 {published data only}
    1. NCT02617589. An Investigational immuno-therapy study of nivolumab compared to temozolomide, each given with radiation therapy, for newly-diagnosed patients with glioblastoma (GBM, a malignant brain cancer) (CheckMate 498). clinicaltrials.gov/study/NCT02617589.
    1. Omuro A, Brandes AA, Carpentier AF, Idbaih A, Reardon DA, Cloughesy T, et al. Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: an international randomized phase 3 trial. Neuro Oncology 2023. Advance Access date 14 April 2022;25(1):123-34. [DOI: 10.1093/neuonc/noac099] - DOI - PMC - PubMed
    1. Sampson JH, Omuro AMP, Preusser M, Lim M, Butowski NA, Cloughesy TF, et al. A randomized, phase 3, open-label study of nivolumab versus temozolomide (TMZ) in combination with radiotherapy (RT) in adult patients (pts) with newly diagnosed, O-6-methylguanine DNA methyltransferase (MGMT)-unmethylated glioblastoma (GBM): CheckMate-498. Journal of Clinical Oncology 2016;34(15_suppl):TPS2079.
Reardon 2020 {published data only}
    1. Lim M, Omuro A, Vlahovic G, et al. Nivolumab (nivo) in combination with radiotherapy (RT) temozolomide (TMZ): Updated safety results from CheckMate 143 inpts with methylated or unmethylated newly diagnosed glioblastoma(GBM). Annals of Oncology 2017;28(Supplement 5):v109.
    1. NCT02017717. A study of the effectiveness and safety of nivolumab compared to bevacizumab and of nivolumab with or without ipilimumab in glioblastoma patients (CheckMate 143). clinicaltrials.gov/study/NCT02017717.
    1. Omuro A, Vlahovic G, Baehring J, Butowski N, Reardon D, Cloughesy T, et al. ATIM-16. Nivolumab combined with radiotherapy with or without temozolomide in patients with newly diagnosed glioblastoma: results from phase 1 safety cohorts in Checkmate 143. Neuro-Oncology 2016;18(suppl_6):vi21.
    1. Omuro A, Vlahovic G, Lim M, Sahebjam S, Baehring J, Cloughesy T, et al. Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143. Neuro-oncology 2018;20(5):674-86. [PMID: ] - PMC - PubMed
    1. Reardon DA, Brandes AA, Omuro A, Mulholland P, Lim M, Wick A, et al. Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial. JAMA Oncology 2020;6(7):1003-10. [PMID: ] - PMC - PubMed
Sim 2023 {published data only}
    1. Sim H, Wachsmuth L, Barnes E, Yip S, Koh E, Hall M, et al. NUTMEG: A randomized phase II study of nivolumab and temozolomide versus temozolomide alone in newly diagnosed older patients with glioblastoma. Neuro-Oncology Advances 22 September 2023;5(1):1-12. [CLINICALTRIALS.GOV: https://clinicaltrials.gov/study/NCT04195139] [DOI: 10.1093/noajnl/vdad124] - DOI - PMC - PubMed
    1. Sim H-W, Lwin Z, Barnes E, McDonald K, Yip S, Verhaak R, et al. A randomized phase II study of nivolumab and temozolomide versus temozolomide alone in newly diagnosed elderly patients with glioblastoma. Neuro-Oncology 2022;5:1-12. - PMC - PubMed

References to studies excluded from this review

Nassiri 2023 {published data only}
    1. Nassiri F, Patil V, Yefet L, Singh O, Liu J, Dang R, et al. CTIM-19. Oncolytic dnx-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial. Neuro-Oncology 2023;25(5):v65-v66. - PMC - PubMed

References to ongoing studies

ChiCTR2000031405 {published data only}
    1. ChiCTR2000031405. Neoadjuvant with continued adjuvant anti-PD-1 antibody versus adjuvant anti-PD-1 alone in treating newly diagnosed resectable glioblastoma: a prospective randomized controlled clinical study. https://trialsearch.who.int/Trial2.aspx?TrialID=ChiCTR2000031405 (first received 30 March 2020).
NCT02287428 {published data only}
    1. NCT02287428. A Phase I study of a personalized neoantigen cancer vaccine with radiotherapy plus pembrolizumab/MK-3475 among newly diagnosed glioblastoma patients. https://clinicaltrials.gov/ct2/show/NCT02287428.
NCT02311920 {published data only}
    1. NCT02311920. Phase I study of ipilimumab, nivolumab, and the combination in patients with newly diagnosed glioblastoma. https://clinicaltrials.gov/ct2/show/NCT02311920. - PMC - PubMed
NCT02794883 {published data only}
    1. NCT02794883. A Phase II, open label, clinical trial of pre-surgical and adjuvant treatment of recurrent malignant glioma with tremelimumab and durvalumab (MEDI4736) alone and in combination to determine immunologic changes from treatment. https://clinicaltrials.gov/ct2/show/NCT02794883.
NCT02852655 {published data only}
    1. NCT02852655. A pilot surgical trial to evaluate early immunologic pharmacodynamic parameters for the PD-1 checkpoint inhibitor, pembrolizumab (MK-3475), in patients with surgically accessible recurrent/​progressive glioblastoma. https://clinicaltrials.gov/study/NCT02852655.
NCT03277638 {published data only}
    1. NCT03277638. Phase I/II study of laser interstitial thermotherapy (LITT) combined with checkpoint inhibitor for recurrent GBM (RGBM). https://clinicaltrials.gov/ct2/show/NCT03277638.
NCT03797326 {published data only}
    1. NCT03797326. A multicenter, open-label phase 2 study of lenvatinib (E7080/MK-7902) plus pembrolizumab (MK-3475) in previously treated subjects with selected solid tumors (LEAP-005). https://clinicaltrials.gov/ct2/show/NCT03797326.
NCT04003649 {published data only}
    1. NCT04003649. A phase 1 study to evaluate IL13Rα2-targeted chimeric antigen receptor (CAR) T cells combined with checkpoint inhibition for patients with resectable recurrent glioblastoma. https://clinicaltrials.gov/ct2/show/NCT04003649.
NCT04195139 {published data only}
    1. NCT04195139. A randomised phase II study of NivolUmab and Temozolomide vs Temozolomide Alone in Newly Diagnosed Elderly patients with Glioblastoma (NUTMEG). https://clinicaltrials.gov/ct2/show/NCT04195139.
NCT04396860 {published data only}
    1. Lassman A, Polly M-Y, Iwamoto F, Sloan A, Wang T, Aldape K, et al. CTIM-18. NRG oncology study bn007:randomized phase ii/iii trial ofipilimiumab (IPI) plus nivolumab(NIVO) vs. temozolomide (TMZ) inmgmt-unmethylated (UMGMT)newly diagnosed glioblastoma(NGBM). Neuro-Oncology 2023;25:v65.
    1. Lassman A, Polly M-Y, Iwamoto F, Sloan A, Wang T, Aldape K, et al. PL02.3.A nrg oncology study bn007:randomized phase ii/iii trial ofipilimiumab (ipi) plus nivolumab(nivo) vs. temozolomide (tmz) inmgmt-unmethylated (umgmt)newly diagnosed glioblastoma(NGBM). Neuro-Oncology 2023;25(Supplement_2):ii2.
NCT04606316 {published data only}
    1. NCT04606316. A phase Ib clinical trial to evaluate early immunologic pharmacodynamic parameters following neoadjuvant anti-PD-1 (Nivolumab), or the combination of anti-PD-1 plus anti-CTLA-4 (Nivolumab Plus Ipilimumab) in patients with surgically accessible glioblastoma. https://clinicaltrials.gov/ct2/show/NCT04606316.
NCT04729959 {published data only}
    1. NCT04729959. Testing the addition of the immune therapy drugs, tocilizumab and atezolizumab, to radiation therapy for recurrent glioblastoma. https://clinicaltrials.gov/study/NCT04729959.
NCT04888611 {published data only}
    1. NCT04888611. Neoadjuvant PD-1 antibody alone or combined with DC vaccines for recurrent glioblastoma. https://clinicaltrials.gov/study/NCT04888611.
NCT05484622 {published data only}
    1. NCT05484622. Study of vorasidenib and pembrolizumab combination in recurrent or progressive enhancing IDH-1 mutant glioma. https://clinicaltrials.gov/study/NCT05484622.

Additional references

Aoki  2021
    1. Aoki T, Kagawa N, Sugiyama K, Wakabayashi T, Arakawa Y, Yamaguchi S, et al. Efficacy and safety of nivolumab in Japanese patients with first recurrence of glioblastoma: an open‐label, non‐comparative study. International Journal of Clinical Oncology 2021;26:2205–15. - PMC - PubMed
Berghoff 2015
    1. Berghoff AS, Kiesel B, Widhalm G, Rajky O, Ricken G, Wöhrer A, et al. Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. Neuro-Oncology 2015;17(8):1064-75. - PMC - PubMed
Cochrane EPOC 2017
    1. Cochrane Effective Practice and Organisation of Care (EPOC). Good practice data extraction form. EPOC resources for review authors, 2017. epoc.cochrane.org/epoc-resources-review-authors (accessed 15 February 2020).
de Groot 2020
    1. Groot J, Penas-Prado M, Alfaro-Munoz K, Hunter K, Pei BL, O'Brien B, et al. Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages. Neuro-Oncology 2020;22(4):539-49. - PMC - PubMed
Doucette 2013
    1. Doucette T, Rao G, Rao A, Shen L, Aldape K, Wei J, et al. Immune heterogeneity of glioblastoma subtypes: extrapolation from the cancer genome atlas. Cancer Immunology Research 2013;1(2):112-22. - PMC - PubMed
FDA 2014
    1. Food and Drug Administration. FDA Drug Approvals. www.fda.gov/drugs/informationondrugs/approveddrugs (accessed: 16 January 2017).
Gilbert 2013
    1. Gilbert MR, Wang M, Aldape KD, Stupp R, Hegi ME, Jaeckle KA, et al. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. Journal of Clinical Oncology 2013;31(32):4085-91. - PMC - PubMed
GRADEpro GDT [Computer program]
    1. GRADEpro GDT. Version accessed 10 January 2021. Hamilton (ON): McMaster University (developed by Evidence Prime), 2021. Available at gradepro.org.
Higgins 2011
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.
Higgins 2020
    1. Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from training.cochrane.org/handbook/archive/v6.1.
Huang 2019
    1. Huang AC, Orlowski RJ, Xu X, Mick R, George SM, Yan PK, et al. A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nature Medicine 2019;25(3):454-61. - PMC - PubMed
Ishida 1992
    1. Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO Journal 1992;11:3887-95. - PMC - PubMed
Keir 2006
    1. Keir ME, Liang SC, Guleria I, Latchman YE, Qipo A, Albacker LA, et al. Tissue expression of PD-L1 mediates peripheral T cell tolerance. Journal of Experimental Medicine 2006;203(4):883-95. - PMC - PubMed
Kreisl 2009
    1. Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. Journal of Clinical Oncology 2009;27:740-5. - PMC - PubMed
Langendam 2013
    1. Langendam MW, Akl EA, Dahm P, Glasziou P, Guyatt G, Schunemann HJ. Assessing and presenting summaries of evidence in Cochrane Reviews. Systematic Reviews 2013;23(2):81. - PMC - PubMed
Liu 2019
    1. Liu J, O'Donnell JS, Yan J, Madore J, Allen S, Smyth M J, et al. Timing of neoadjuvant immunotherapy in relation to surgery is crucial for outcome. Oncoimmunology 2019;8(5):e1581530. - PMC - PubMed
Louis 2007
    1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathologica 2007;114(2):97-109. - PMC - PubMed
Louis 2016
    1. Louis DN, Perry A, Reifenberger G, Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathologica 2016;131(6):803-20. - PubMed
Lu 2021
    1. Lu Y, Ng AHC, Chow FE, Everson RG, Helmink BA, Tetzlaff MT, et al. Resolution of tissue signatures of therapy response in patients with recurrent GBM treated with neoadjuvant anti-PD1. Nature Communication 2021;12(1):4031. - PMC - PubMed
Meader 2014
    1. Meader N, King K, Llewellyn A, Norman G, Brown J, Rodgers M, et al. A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation. Systematic Reviews 2014;3:82. - PMC - PubMed
Melo 2017
    1. Melo SM, Moraes FY, Porfírio GJM, Silva MEN, De Cicco K, Torloni MR, et al. Immune checkpoint blockade for glioma. Cochrane Database of Systematic Reviews 2017, Issue 1. Art. No: CD012532. [DOI: 10.1002/14651858.CD012532] - DOI
Memarnejadian 2017
    1. Memarnejadian A, Meilleur CE, Shaler CR, Khazaie K, Bennink JR, Schell TD, et al. PD-1 blockade promotes epitope spreading in anticancer CD8. Journal of Immunology 2017;199(9):3348-59. - PMC - PubMed
NCI 2018
    1. National Cancer Institute. Common terminology criteria for adverse events (v5.0). ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_50.
Nduom 2016
    1. Nduom EK, Wei J, Yaghi NK, Huang N, Kong LY, Gabrusiewicz K, et al. PD-L1 expression and prognostic impact in glioblastoma. Neuro-Oncology 2016;18(2):195-205. - PMC - PubMed
Okada 2015
    1. Okada H, Weller M, Finocchiaro G, Gilbert MR, Wick W, Ellingson BM, et al. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncology 2015;16(15):e534-42. - PMC - PubMed
Ostrom 2019
    1. Ostrom QT, Cioffi G, Gittleman H, Patil N, Waite K, Kruchko C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012-2016. Neuro-Oncology 2019;21(Suppl 5):v1-100. - PMC - PubMed
Postow 2015
    1. Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. New England Journal of Medicine 2015;372(21):2006-17. - PMC - PubMed
Prins 2010
    1. Prins RM, Soto H, Konkankit V, Odesa SK, Eskin A, Yong WH, et al. Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. American Association for Cancer Research 2010;17(6):1603-15. - PMC - PubMed
Rao 2020
    1. Rao G, Latha K, Ott M, Sabbagh A, Marisetty A, Ling X, et al. Anti-PD-1 induces M1 polarization in the glioma microenvironment and exerts therapeutic efficacy in the absence of CD8 cytotoxic T cells. Clinical Cancer Research 2020;26(17):4699-712. - PMC - PubMed
Reardon 2021
    1. Reardon DA, Kim TM, Frenel JS, Simonelli M, Lopez J, Subramaniam DS, et al. Treatment with pembrolizumab in programmed death ligand 1-positive recurrent glioblastoma: Results from the multicohort phase 1. Cancer 2021;127(10):1620-9. - PubMed
Reck 2016
    1. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. New England Journal of Medicine 2016;375:1823-33. - PubMed
RevMan 2024 [Computer program]
    1. Review Manager (RevMan). Version 8.7.0. The Cochrane Collaboration, 2024. Available at revman.cochrane.org.
Schalper 2019
    1. Schalper K, Rodriguez-Ruiz M, Diez-Valle R, López-Janeiro A, Porciuncula A, Idoate M, et al. Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma. Nature Medicine 2019;25:470-476. [DOI: 10.1038/s41591-018-0339-5] - DOI - PubMed
Schünemann 2020
    1. Schünemann HJ, Higgins JP, Vist GE, Glasziou P, Akl EA, Skoetz N, Guyatt GH. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from training.cochrane.org/handbook/archive/v6.1.
Scott 2008
    1. Scott NW, Fayers PM, Aaronson NK, Bottomley A, Graeff A, Groenvold M, et al. EORTC QLQ-C30 Reference Values. Brussels: EORTC Quality of Life Group Publications, 2008.
Taphoom 2010
    1. Taphoorn MJ, Claassens L, Aaronson NK, Coens C, Mauer M, Osoba D, et al, EORTC quality of life group and brain cancer, NCIC and radiotherapy groups. An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients. European Journal of Cancer 2010;46(6):1033-40. - PubMed
Tierney 2007
    1. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8(1):16. - PMC - PubMed
WHO 2020
    1. World Health Organization. International agency for research on cancer. GLOBOCAN 2020: cancer statistics for the year 2020: an overview. https://onlinelibrary.wiley.com/doi/10.1002/ijc.33588 (accessed 11 August 2021).
Woroniecka 2018
    1. Woroniecka K, Chongsathidkiet P, Rhodin K, Kemeny H, Dechant C, Farber SH, et al. T-Cell exhaustion signatures vary with tumor type and are severe in glioblastoma. Clinical Cancer Research 2018;24(17):4175-86. - PMC - PubMed
Wu 2010
    1. Wu W, Lamborn KR, Buckner JC, Novotny PJ, Chang SM, O’Fallon JR, et al. Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma. Neuro-Oncology 2010;12:164-72. - PMC - PubMed
Zhao 2019
    1. Zhao J, Chen AX, Gartrell RD, Silverman AM, Aparicio L, Chu T, et al. Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. Nature Medicine 2019;25(3):462-9. - PMC - PubMed

MeSH terms

Associated data

LinkOut - more resources